, an analyst from BMO Capital, has initiated a new Buy rating on IQVIA Holdings (IQV).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
BMO Capital’s rating is based on several key factors that suggest a positive outlook for IQVIA Holdings. The firm has observed that the recent challenges faced by IQVIA, primarily due to pharmaceutical R&D rationalizations, are beginning to subside. This change is expected to lead to an acceleration in earnings per share (EPS) and a more favorable price-to-earnings (P/E) ratio by 2026, as the worst of the cancellations appear to be in the past.
BMO Capital also highlights IQVIA’s significant investments in technology and data assets, which provide a competitive advantage in the drug development and commercialization space. With a vast collection of healthcare data and advanced AI tools, IQVIA is well-positioned to enhance its operational efficiency and differentiate itself from competitors. Additionally, the improving outlook for biotech funding further supports the potential for growth, justifying the Buy rating and a target price of $260 per share.
In another report released on October 29, UBS also maintained a Buy rating on the stock with a $250.00 price target.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IQV in relation to earlier this year.